テキサスにおける慢性リンパ性白血病の臨床試験
テキサス内の拠点で、慢性リンパ性白血病に関する38件の研究が参加者を募集しています。
テキサス内の都市
公式研究テキスト（英語）
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- Houston Methodist Hospital, Houston
- Texas Children's Hospital, Houston
被験者募集中第1相
75歳以下 · 全性別 · 2026/10/02更新 · NCT01853631Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
- Hendrick Medical Center, Abilene
被験者募集中第3相
65歳以上 · 全性別 · 2026/10/02更新 · NCT07321652Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- The Don and Sybil Harrington Cancer Center, Amarillo
- UT MD Anderson Cancer Center, Houston
- Audie L Murphy VA Hospital, San Antonio
被験者募集中観察研究健康なボランティア歓迎
40歳〜75歳 · 全性別 · 2026/10/02更新 · NCT05334069A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
- Research Site, Houston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/30更新 · NCT06542250A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
- Texas Oncology Baylorcharles A Sammons Cancer Center, Dallas
- Texas Oncology San Antonio Medical Center Usor, San Antonio
- Texas Oncology Tyler, Tyler
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/28更新 · NCT06943872A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Md Anderson Cancer Center, Houston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/28更新 · NCT05006716A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
- Texas Oncology Tyler, Tyler
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/28更新 · NCT07277231A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
- Baylor Scott and White Health, Temple
- Texas Oncology Tyler, Tyler
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/28更新 · NCT06846671A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Md Anderson Cancer Center, Houston
- Texas Oncology Palestine Cancer Center, Palestine
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/28更新 · NCT06973187A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
- PatientCare Clinical Research LLC ( Site 5435), Sugar Land
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/24更新 · NCT05947851A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
- Texas Oncology - Central/South Texas ( Site 8008), Austin
- The Center for Cancer and Blood Disorders ( Site 0032), Fort Worth
- Texas Oncology - San Antonio ( Site 8006), San Antonio
- 他1件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/24更新 · NCT06136559A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Texas Oncology - Paris, Fort Worth
- US Oncology - Texas Oncology, Kyle
被験者募集中第4相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07218341Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- The University of Texas MD Anderson Cancer Center, Houston
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/21更新 · NCT07648264A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
- Texas Oncology - Center South, Austin
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/17更新 · NCT07221500Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- M D Anderson Cancer Center, Houston
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/10更新 · NCT04169737A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
- Research Site, Houston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/08更新 · NCT06564038Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Baylor University Medical Center, Dallas
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/08更新 · NCT03666000Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
- Baylor Scott & White Health, Dallas
- MD Anderson, Houston
被験者募集中第1/2相
12歳以上 · 全性別 · 2026/09/03更新 · NCT04588922Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL
- Texas Oncology - West Texas, Midland
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/31更新 · NCT07516093Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
- Texas Oncology - Northeast, Tyler
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/28更新 · NCT07520006A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Lumi Research, Kingwood
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/17更新 · NCT05254743Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- University of Texas MD Anderson Cancer Center, Houston
被験者募集中第1/2相
13歳〜90歳 · 全性別 · 2026/08/06更新 · NCT06533579A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies
- UT Southwestern Medical Center, Dallas
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/31更新 · NCT06708897Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).
- MD Anderson Cancer Center, Houston
被験者募集中第2相
18歳以上 · 全性別 · 2026/07/30更新 · NCT06967610A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- MD Anderson Cancer Center, Houston
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/02更新 · NCT05131022A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
- Texas Oncology - Sammons Cancer Center, Dallas
被験者募集中第2相
18歳以上 · 全性別 · 2026/06/12更新 · NCT07271667A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- USO-Texas Oncology-Central/South Texas, Austin
- Sarah Cannon Research Institute/SCRI, The Woodlands
被験者募集中第2相
18歳以上 · 全性別 · 2026/05/19更新 · NCT06588478Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
- MD Anderson Cancer Center, Houston
被験者募集中第1相
13歳以上 · 全性別 · 2026/05/05更新 · NCT04771572The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
- University of Texas(UT) Southwestern-Children's Medical Center, Dallas
被験者募集中第1/2相
12歳〜95歳 · 全性別 · 2026/04/15更新 · NCT04329728A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
- Texas Oncology - Austin Midtown /ID# 268152, Austin
- University of Texas - Southwestern Medical Center /ID# 266528, Dallas
被験者募集中第3相
18歳以上 · 全性別 · 2026/04/09更新 · NCT06428019A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
- MD Anderson Cancer Center, Houston
被験者募集中第1相
18歳以上 · 全性別 · 2026/03/20更新 · NCT04830137A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
- University of Texas MD Anderson Cancer Center, Houston
被験者募集中第4相
18歳以上 · 全性別 · 2026/03/02更新 · NCT06876662A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
- University of Texas MD Anderson Cancer Center, Houston
被験者募集中第4相
18歳以上 · 全性別 · 2026/03/02更新 · NCT06876649Study of SGR-1505 in Mature B-Cell Neoplasms
- University of Texas Southwestern, Dallas
被験者募集中第1相
18歳以上 · 全性別 · 2026/02/13更新 · NCT05544019AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
- Oncology Consultants, Houston
- University of Texas MD Anderson Cancer Center, Houston
被験者募集中第1相
18歳以上 · 全性別 · 2025/12/10更新 · NCT05602363A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
- SCRI, San Antonio
被験者募集中第1/2相
18歳以上 · 全性別 · 2025/11/14更新 · NCT05643742A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
- University of Texas Southwestern Medical Center, Dallas
被験者募集中第1相
18歳以上 · 全性別 · 2025/10/02更新 · NCT05780034Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
- UT Southwestern Medical Center, Dallas
被験者募集中第1/2相
18歳以上 · 全性別 · 2022/08/04更新 · NCT04502394ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。